The medication is commonly used in situations involving certain distressing symptoms, applying across domains where additional symptomatic support is needed. The compound is considered relevant for its supportive effects during periods of heightened physiological stress.

Glycine is generally used to help manage symptoms related to systemic imbalance, including symptoms related to psychoemotional stress, nervous tension, and functional sleep difficulties. It is also relevant for managing symptoms of mental fatigue when symptoms create noticeable physiological strain. Furthermore, it is relevant in clinical settings that involve acute or unstable symptom patterns, such as providing support during complex recovery phases where symptoms may intensify temporarily.

“The medication is commonly used when symptoms become temporarily overwhelming and short-term symptomatic assistance is needed.”

In these symptomatic areas, the medication may assist with maintaining functional stability and supports patients during difficult episodes by easing distress.

---

Quick Fact: Support for Nervous Tension and Sleep Symptoms

Glycine is commonly used to help manage symptoms related to nervous system overstimulation and functional sleep difficulties, providing supportive relief that helps patients cope more steadily during symptomatic periods and contributes to easing the overall symptom load.

The official regulatory profile for Глицин strictly defines the populations who can and cannot use the medicine based on formal eligibility statements and regulatory classifications.

Eligibility Scope

Category	Status According to Regulatory Documents
Allowed Use	Adults and adolescents; Children meeting the minimum age threshold (e.g., typically 3 years and older).
Contraindicated	Individuals with individual hypersensitivity to glycine or any tablet component.
Not Recommended	Pregnant women and breastfeeding women.
Condition-Specific Rules	Contraindicated in some territories for patients with arterial hypotension (low blood pressure).

---

Eligibility Classifications (High-Level)

Age-related eligibility rules: Use is restricted or contraindicated for children below a minimum age threshold (e.g., under 3 years old) in the prescribing information for certain authorized formulations.

Pregnancy and lactation eligibility status: Formally classified as Not Recommended or Contraindicated due to the official acknowledgment of insufficient safety data for these physiological states.

Eligibility-related restrictions: Caution is required for patients with a predisposition to arterial hypotension, as the medicine may cause a further reduction in blood pressure.

---

Connection to the overall eligibility profile

The regulatory profile establishes eligibility for Глицин based on two primary factors: absolute exclusion due to known hypersensitivity or a specific comorbidity, and temporary exclusion based on the regulatory judgment of insufficient safety data for certain physiological statuses. All other populations, including adults and children meeting the minimum age threshold, are permitted to use the medicine under standard labeled conditions as defined by national regulatory authorities.

Official Regulatory Information for Глицин

This section outlines the officially documented interaction profile for Глицин (Glycine) as detailed in national regulatory documentation. The focus is on observed pharmacodynamic effects and specific limitations on co-administration.

Property	Value
Medicinal Product Categories	CNS Depressants (Anxiolytics, Neuroleptics, Hypnotics); Antidepressants; Anticonvulsants; Antihypertensive Drugs.
Specific Interacting Medicines	Clozapine (Regulatory guidance advises against co-administration due to potential for decreased efficacy).
Mechanistic Basis	Pharmacodynamic interaction (Additive CNS effects; Modification of side-effect profiles).
Timing/Separation Rules	None officially documented in regulatory labeling.

Interaction Classifications

The interactions are primarily classified as clinically significant pharmacodynamic effects. Regulatory advice places a prohibition or strong caution on combining Глицин with Clozapine. Other interactions are typically classified as "Use with Caution" based on the observed additive effects.

Official Interaction Statements

• Co-administration with Central Nervous System Depressants (including anxiolytics and hypnotics) may result in an enhanced CNS inhibition due to an additive effect.
• Глицин is documented to weaken the severity of side effects of co-administered antidepressants and anticonvulsants.
• The co-administration of Глицин with certain Antihypertensive Drugs may enhance the blood pressure-lowering effect.
• Interaction with alcohol is documented as enhancing the calming properties of Глицин.

Regulatory documents define the product’s interaction structure through direct pharmacodynamic effects with psychotropic agents, specifying outcomes that include enhanced inhibition and the modification of specific side-effect profiles. This profile includes a formal constraint against combination with the specific antipsychotic Clozapine.

Central Inhibition via Chloride Ion Channels

The primary action involves direct agonism at the Glycine Receptors ( GlyRs), which are ligand-gated chloride ion channels found predominantly in the brainstem and spinal cord. When activated, these channels cause hyperpolarization of the neuronal membrane , increasing the threshold for firing. This mechanism results in a systemic decrease in net CNS excitability.

---

Modulation of the Excitatory NMDA Pathway

Glycine also functions as an essential co-agonist at the NMDAR, a crucial receptor for glutamatergic excitatory signaling. By occupying a necessary binding site, Glycine modulates the responsiveness of the NMDAR. This modulatory mechanism influences NMDAR-dependent signaling, a pathway essential for synaptic plasticity.

---

Metabolic Substrate Provision for Neuroprotection

The molecule acts as a metabolic substrate crucial for the synthesis of key biochemical compounds, most significantly the major endogenous antioxidant, Glutathione. This pathway provides necessary substrate for the synthesis of Glutathione, an endogenous antioxidant that mediates the defense against oxidative stress and contributes to the maintenance of neuronal tissue integrity.

The use of Глицин (Glycine) is defined by the product’s instructions, which provide the administration method, dosing schedule, duration of use, and population-specific guidelines. The medication is intended for short-course use, with dosage and frequency based on the specific context of use.

---

Administration Scope

Instruction	Detail
Route of administration	Sublingual (under the tongue) or buccal (against the cheek/gum). The tablet is to be dissolved in the mouth.
Dosing schedule (General Use)	Standard Dose: 100 mg per administration. Maximum daily intake for general use is typically 300 mg.
Timing in relation to meals	Instructions do not specify administration timing in relation to food intake.
Preparation requirements	The tablet may be administered intact or as a powder after crushing to facilitate sublingual or buccal intake.
Age-group administration rules	Adults and Children over 3 years old receive 100 mg per dose. Children under 3 years old are prescribed a reduced dose of 50 mg (half a tablet) per dose.
Special procedural conditions	For use in functional sleep difficulties, the dose is taken 20 minutes before going to sleep or immediately before going to sleep.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral-mucosal (designed for rapid absorption through the mouth lining).
Frequency pattern	Multiple times daily (2–3 times a day) or contextual (single dose before bedtime).
Regulatory basis	Established medical registers and standard pharmacological guidelines.
Use-context constraints	Use is defined by a mandatory, fixed-duration course lasting 14 to 30 days.

---

Resulting Procedural Structure

Official step sequence:

• The 100 mg tablet is placed under the tongue or against the cheek and allowed to dissolve.
• The dose is repeated 2 to 3 times a day for a course lasting 14 to 30 days.
• Administration for sleep support requires the dose to be accurately timed just prior to bedtime.

Connection to the overall use protocol (2–4 sentences): These instructions establish a standardized, non-parenteral delivery method (sublingual/buccal) designed to facilitate absorption through the oral mucosa. The protocol specifies fixed daily doses, a maximum daily limit, and a defined duration of use, which collectively structure the entire course of therapy as documented in the pharmacological information.

Research Evidence / Overview of Studies for Глицин (Glycine)

---

Evidence for Use in Functional Sleep Difficulties and Poor Sleep Quality

The research exploring how symptoms change over time in conditions related to sleep quality concerns have been explored through short-term Randomized Controlled Trials (RCTs) and smaller human intervention studies. These studies were applied in research contexts involving fluctuating or unstable symptoms, particularly in healthy adults who described subjective experiences such as unsatisfactory sleep or feelings of fatigue upon waking. Research explored patient-reported outcomes for sleep quality, where participants rated their experiences using questionnaires, and also monitored objective sleep parameters, such as the time taken to fall asleep, using advanced monitoring methods.

Studies focusing on episodes where symptoms become more noticeable reported that research highlights changes measured during the study period, particularly regarding patient-reported outcomes describing perceived discomfort with sleep quality and feelings of alertness the following day. The reported measurements were mixed across studies that monitored objective sleep parameters, such as the actual duration of sleep. Reported outcomes were short-term and based on small sample sizes, meaning the evidence contributes to the broader research landscape, but the limited scope of the studies restricts overall certainty.

---

Evidence for Supportive Effects during Psychoemotional Stress and Cognitive Load

Research explored Glycine in contexts involving acute mental demands, often in healthy young and middle-aged adults who were subjected to mental stress or experimental sleep restriction. The studies monitored outcomes reflecting daily functioning or activity level, such as performance on cognitive tests designed to measure attention, reaction time, and psychomotor vigilance. They also explored outcomes related to systemic or functional imbalance, such as subjective feelings of mental fatigue and stress levels.

---

Key Uncertainties and Research Gaps

Despite the existing research, several areas of uncertainty and key research gaps remain. Long-term effects are not fully established, and more studies monitoring patient responses over several months could provide insight into potential sustained patterns. The evidence is limited regarding how broadly any observed patterns apply across the general population, as sample sizes were modest in many trials. Overall, research provides context but not individual predictions, and more extensive, rigorous studies would help expand the evidence landscape.

Common questions about Глицин (FAQ)

---

Q: Is Глицин considered a tranquilizer or a sedative medicine?

Official sources categorize Глицин primarily as a Metabolic agent and a Central Nervous System (CNS) regulator. Slight sedation or drowsiness is noted as a possible, generally mild side effect for the oral tablet.

Q: Is there official information about Глицин and its use in children or adolescents?

Yes, regulatory instructions define use based on age. Official guidance permits Глицин for use in adults and adolescents, and in children over 3 years old at the standard amount. For children under 3 years old, the drug information specifies a reduced dosage amount compared to the standard amount for older age groups, according to administration rules.

Q: Why do some people take Глицин for study or focus?

Official documentation describes the general purpose of Глицин as providing support for managing psychoemotional stress and stabilizing mood. Research has explored its supportive effects during periods of high cognitive load, which aligns with concerns related to mental demands.

Q: Are allergic reactions to Глицин common, and what are the signs?

Regulatory documents state that allergic reactions, known as hypersensitivity, are rare for the oral tablet formulation. Official safety summaries mention the risk of hypersensitivity as a contraindication, but do not typically detail the specific physical signs of a reaction.

Q: Do official patient information leaflets mention issues related to pregnancy or breastfeeding?

Yes. The official regulatory profile classifies the use of Глицин in both pregnant women and breastfeeding women as Not Recommended or Contraindicated. This classification is based on regulatory judgment acknowledging the insufficient safety data available for these specific physiological states.

Q: What is the maximum duration of use that has been studied for Глицин?

Regulatory instructions define the authorized usage period for the medicine as a fixed duration course, typically lasting 14 to 30 days. Research evidence indicates that studies have primarily been of a short-term nature, and the long-term effects are noted as not being fully established.

Q: Is the absorption of Глицин affected by taking it with food?

The official regulatory instructions for Глицин do not specify administration timing in relation to food intake. The drug is administered sublingually or buccally, designed to be absorbed through the mouth lining.

Q: Do regulatory bodies consider Глицин to be a drug or a dietary supplement?

The product is formally defined in established medical registries as a Metabolic agent and a Central Nervous System (CNS) regulator. It is also widely recognized as an Over-the-Counter (OTC) preparation in many regions, classifying it based on its pharmacological action.

Q: Is Глицин a prescription medicine in all countries, or just some?

Regulatory information notes that Глицин is generally recognized as an Over-the-Counter (OTC) preparation in many regions. This indicates that its classification is not universally restricted to prescription-only status, but its availability may vary by country.

Q: What are the different strengths or formats (e.g., tablet size) that Глицин is commonly sold in?

Official instructions typically refer to a 100 mg tablet. The medicine is authorized and sold in the form of Sublingual tablets or Buccal tablets, which are designed to dissolve in the mouth.

Q: What is the general level of evidence available for the claims made about Глицин?

Research evidence is generally described as consisting of short-term Randomized Controlled Trials (RCTs) with modest sample sizes. Official sources note that the limited scope of these studies restricts the overall certainty about broad patient patterns.

Q: Does Глицин interact with alcohol, according to official sources?

Yes. Official interaction statements document that the co-administration of Глицин with alcohol enhances the calming properties of the medicine due to an additive pharmacodynamic effect.

Q: Are there different forms of the drug (e.g., 'glycine forte') and what do they mean?

The medicine is defined in regulatory documents as a single-ingredient product, containing only the active substance Glycine (Aminoacetic acid). The regulatory profile does not officially define or recognize variations such as 'glycine forte'.

Q: Why do official sources sometimes use the term 'metabolic regulator' for Глицин?

Official sources use the classification of Metabolic agent or regulator because Glycine acts as a metabolic substrate. This substrate is crucial for the body's synthesis of key compounds, such as the major endogenous antioxidant Glutathione.

Q: How is the safety profile of Глицин generally described in regulatory documents?

The safety profile for the oral tablet is generally described in official sources as associated with adverse effects that are typically mild and infrequent. This is based on safety data collected from authorized use.

Q: Is there any information regarding Глицин and its effect on blood pressure?

Yes. Safety restrictions note that the medicine may cause a reduction in blood pressure. Patients with a known tendency toward arterial hypotension (low blood pressure) must have their blood pressure closely monitored during the course of use.

Q: Is it known if Глицин can be crushed, chewed, or dissolved?

Regulatory guidance specifies that the tablet is designed to be dissolved in the mouth (sublingual or buccal) for absorption. The administration rules also state that the tablet may be administered intact or as a powder after crushing.

Q: What evidence exists regarding Глицин's use for anxiety symptoms?

Official general purposes include support for managing conditions of psychoemotional stress and anxiety. Research studies have explored the supportive effects of Глицин during periods of psychoemotional stress.

Q: Are there official warnings about combining Глицин with other psychiatric drugs?

Official interaction statements advise caution when co-administering with certain drug classes, including Central Nervous System Depressants. Глицин is documented to weaken the severity of side effects of co-administered antidepressants and anticonvulsants. A formal constraint is placed against combination with the specific antipsychotic Clozapine.

Q: What is the legal classification of Глицин (e.g., OTC, Schedule) in various regions?)

The medicine is noted to be generally recognized as an Over-the-Counter (OTC) preparation in many regions in established medical registries. This refers to its classification for sale and accessibility.

Official Storage and Disposal Requirements

Scope Item	Official Regulatory Statement
Labeled Temperature	Store at or below 30°C (Controlled Room Temperature).
Protection	Must be stored in a dry place and protected from light.
Packaging Rule	Keep the medicine in the original packaging to ensure physical protection.
Child Safety	Keep out of the sight and reach of children.

Regulatory documents specify that Глицин tablets must be stored at a maximum temperature of 30°C, and they must be protected from both light and moisture to maintain product stability. Storage in the original container helps preserve this protection. Any unused or expired product must be disposed of strictly in accordance with local requirements for pharmaceutical waste, which helps prevent environmental contamination.